Bio-Techne Launches Next-Gen Leo System, Enhancing Data Processing Efficiency
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 day ago0mins
- Technological Innovation: Bio-Techne's next-generation Leo™ System combines dual-channel fluorescence detection with chemiluminescence, significantly enhancing data throughput and efficiency, enabling researchers to simultaneously quantify targets with distinct expression levels, thus advancing the study of complex biological questions.
- Increased Experimental Flexibility: The new system's fluorescence capability adds a fourth multiplexing option to molecular weight separation, RePlex, and resampling, allowing for the processing of up to 100 capillaries in a single run, greatly improving experimental flexibility and efficiency.
- High Precision Results: The Leo system's high-throughput capabilities achieve highly precise results with only 5-6% variability, setting a new standard for clinical research that requires absolute quantitation, thereby meeting critical demands in the field.
- Market Impact: With over $1.2 billion in net sales for fiscal 2025, the launch of the Leo system is expected to further enhance Bio-Techne's competitiveness in the life sciences tools market, facilitating accelerated critical discoveries and streamlined development timelines.
TECH.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on TECH
Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 67.50 USD with a low forecast of 60.00 USD and a high forecast of 73.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 58.820
Low
60.00
Averages
67.50
High
73.00
Current: 58.820
Low
60.00
Averages
67.50
High
73.00
Baird
Catherine Ramsey Schulte
Neutral
downgrade
$62 -> $61
2025-11-06
Reason
Baird
Catherine Ramsey Schulte
Price Target
$62 -> $61
2025-11-06
downgrade
Neutral
Reason
Baird analyst Catherine Ramsey Schulte lowered the firm's price target on Bio-Techne to $61 from $62 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
UBS
Buy
maintain
$65 -> $70
2025-11-06
Reason
UBS
Price Target
$65 -> $70
2025-11-06
maintain
Buy
Reason
UBS raised the firm's price target on Bio-Techne to $70 from $65 and keeps a Buy rating on the shares.
Evercore ISI
Outperform
to
NULL
downgrade
$72 -> $68
2025-11-06
Reason
Evercore ISI
Price Target
$72 -> $68
2025-11-06
downgrade
Outperform
to
NULL
Reason
Evercore ISI lowered the firm's price target on Bio-Techne to $68 from $72 and keeps an Outperform rating on the shares. The firm said it is trimming expectations for organic growth due to timing issue with cell therapy customers, yet the macro recovery thesis remains intact.
TD Cowen
Kyle Boucher
Buy
maintain
$65 -> $70
2025-10-14
Reason
TD Cowen
Kyle Boucher
Price Target
$65 -> $70
2025-10-14
maintain
Buy
Reason
TD Cowen analyst Kyle Boucher raised the firm's price target on Bio-Techne to $70 from $65 and keeps a Buy rating on the shares. The firm noted consensus estimates have moved lower since F4Q earnings, and while they lowered their estimates for 1H2026 given difficult year-over-year comparisons, they maintain their positive view on shares.
See All Ratings
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?